Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-c CD8 þ and CD4 þ and CD4 þ T-cell markers were 68.1 and 61.8%, respectively. Recipients of grafts from CMV seropositive, related or HLA-matched donors, or receiving non-myeloablative conditioning had nonsignificant tendencies to reach more frequently protective levels of both T-cell subsets at early and late (day þ 365) times after transplantation. The use of antithymocyte globulin and umbilical cord blood transplantation were associated with impaired CMV-specific T-cell reconstitution. CMV-specific IFN-c CD8 þ and CD4 þ T-cell recovery occurred irrespective of detectable CMV DNAemia.
Introduction
Protection from active CMV infection in the allo-SCT setting is critically dependent on reconstitution of functional CMVspecific CD8 þ and CD4 þ T cells. [1] [2] [3] [4] [5] Quantification of CMVspecific T cells has been shown to be potentially helpful in identifying patients at higher risk for developing CMV-related clinical complications. 6 Pre-emptive antiviral therapy, currently the strategy of first choice to prevent the occurrence of CMV end-organ disease in allo-SCT recipients, 7 leads to significant over-treatment, which may result in toxicity, development of antiviral resistance or late-onset CMV disease. 8 Hopes have been raised that routine immunological monitoring may lead to a more targeted use of pre-emptive therapy. Several surrogate immunological markers for adaptive immune competence against CMV have been proposed. 6 Moreover, threshold levels of certain CMV-specific T-cell populations presumably affording protection from active CMV infection and disease have been temptatively established, though their clinical utility awaits further validation. [9] [10] [11] [12] [13] [14] [15] [16] In a pilot study, we showed that quantification of CD8 þ and CD4 þ T cells producing IFN-g on stimulation with two peptide libraries encompassing the entire sequence of pp65, and IE-1 allowed the identification of patients presumably protected from CMV DNAemia early after transplantation.
14 A protective threshold level in the number of both IFN-g T-cell subsets showing maximum specificity was established (41.0 cell/mL for IFN-g CD8 þ T cells and 41.2 cells/mL for and IFN-g CD4 þ T cells). In this study, we further tested the predictive value of the aforementioned threshold cell levels in a large cohort of allo-SCT recipients, and investigated the effects of pre-transplant, clinical and virological factors on the rate and magnitude of early and long-term reconstitution of both CMV-specific IFN-g T-cell populations.
Patients and methods

Patients
The study group consisted of 133 patients who had undergone T-cell-replete allo-SCT between January 2007 and May 2009 at four Spanish hospitals. Patients were followed up to 1 year after transplantation. The demographic and clinical characteristics of patients are summarized in Table 1 . The study was approved by the respective ethics committees, and all patients gave their informed consent to participate.
Virological monitoring and management of active CMV infection Virological monitoring of active CMV infection was performed by the pp65 antigenemia assay (Diagnostics CMV pp65 Antigenemia Immunofluorescence assay, Chemicon International, Temecula, CA, USA) and/or by a plasma real-time PCR assay (CMV real-time PCR, Abbott Molecular, Des Plaines, IL, USA or LightCycler CMV Quant Kit, Roche, Branchburg, NJ, USA) as previously reported. 14, 17 Pre-emptive therapy with oral valganciclovir (900 mg/12 h), i.v. ganciclovir (5 mg/kg/12 h) or i.v. foscarnet (60 mg/kg/12 h) was initiated and discontinued following previously published criteria.
14 CMV end-organ disease was diagnosed and treated as previously reported. 18 Immunological monitoring Enumeration of CMV-specific IFN-g-producing CD8 þ and CD4
þ T cells was carried out by flow cytometry for ICS (BD Fastimmune, BD-Beckton Dickinson and Company-Biosciences, San Jose, CA, USA) as previously described.
14 Two sets of 15-mer overlapping peptides encompassing the entire sequence of CMV pp65 and IE-1 proteins were simultaneously used for stimulation. Immunological monitoring was scheduled to be performed at days þ 30, þ 60, þ 90 and þ 365 following allo-SCT.
Statistical analysis
Data were analyzed with the aid of the statistical package SPSS (Chicago, IL, USA, version 17.0). Frequency comparisons were carried out using the w 2 -test (Fisher's exact test) for categorical variables. Differences between medians were compared using the Mann-Whitney U-test (two independent variables) or the Kruskal-Wallis test (k independent variables) for unpaired data. The Spearman's rank test was used for analysis of correlation between continuous variables. Two-sided exact P-values are reported. A P-value o0.05 was considered statistically significant.
Results
Incidence of CMV DNAemia and CMV end-organ disease
In all 89 (66.9%) out 133 patients developed one (n ¼ 74) or more (n ¼ 15) episodes of CMV DNAemia (in total, 106 episodes) within the study period. All these episodes were pre-emptively treated. Univariate analysis revealed a significant association between receipt of grafts from HLA-mismatched or unrelated donors and the development of CMV DNAemia (Table 2) . CMV end-organ disease developed in 10 patients (7.5%; two pneumonitis, seven gastrointestinal disease and one retinitis) and was not significantly associated with any pre-transplant or clinical factor subjected to analysis (not shown).
CMV-specific IFN-g þ CD8 þ and IFN-g CD4 þ T-cell threshold levels predicting protection from CMV DNAemia Blood specimens from 116 patients obtained at day þ 30 (median, 35 days; range, 12-49 days) were available for immunological analysis. In all, 23 of these patients had an episode of CMV DNAemia before or at the time of sample collection and were excluded from analysis. In all, 27 out of the remaining 93 patients developed CMV DNAemia after the time of immunological monitoring. Peripheral levels of CMV-specific IFN-g CD8 þ and CD4 þ T cells were significantly lower (Po0.001) in patients who later experienced CMV DNAemia (median, 0 cells/mL for both T-cell subsets) than in those who did not (median 1.0 cells/mL, for IFN-g CD8 þ T cells; median 0.84 cells/mL, for IFN-g CD4 þ T cells). Individual data are shown in Figure 1 .
T-cell counts 41.0 cells/mL and 41.2 cells/ mL, respectively, or both (n ¼ 14) at day þ 30 developed CMV DNAemia during the study period (positive predictive value of 100% for both T-cell markers). The negative predictive values for the IFN-g CD8 þ T-cell marker, the IFN-g CD4 þ T-cell marker, for either one marker, and for the combination of both were 68.1, 61.8, 71.2 and 59.4%, respectively.
Patients showing levels of either IFN-g T-cell subset above thresholds at day þ 30 remained protected during the entire study period (not shown).
Immunological data at days þ 60 and þ 90 were available from 22 and 40 patients, respectively, who had developed and cleared an episode of CMV DNAemia. No patients exhibiting either CMV-specific IFN-g CD8 þ or IFN-g CD4 þ T-cell levels above the established thresholds for protection had a recurrent episode of CMV DNAemia, which only occurred (n ¼ 9) in the face of IFN-g CD8 þ and IFN-g CD4 þ T-cell levels below thresholds.
Effects of pre-transplant, clinical and virological factors on early and long-term reconstitution of CMV-specific IFN-g CD8 þ and CD4 þ T-cell responses Overall, the percentage of patients presumably protected from CMV DNAemia (either IFN-g T-cell subset above defined thresholds) at days þ 30, þ 90 and þ 365 (median, þ 360; range, þ 304 to þ 405) were 27.9% (26 out of 93), 67% (52 out of 77) and 89.1% (49 out of 55), respectively.
Among patients with no previous CMV DNAemia, peripheral levels of CMV-specific IFN-g CD8 þ and IFN-g CD4 þ T cells at day þ 30 were significantly higher in patients who had received transplants from CMV seropositive (medians, 0.33 cell/mL and 0.22 cell/mL, respectively) or related donors (medians, 0.30 and 0.36 cell/mL, respectively), compared with patients receiving transplants from CMV seronegative (median 0 cell/mL for both T-cell subsets; P ¼ 0.039, and P ¼ 0.05, respectively) or unrelated donors (median 0 cell/mL for both T-cell subsets; P ¼ 0.020 and P ¼ 0.023, respectively). Use of anti-thymocyte globulin (ATG) had a significant impact on the magnitude of IFN-g CD8 þ and IFN-g CD4 þ T-cell responses at this time point (P ¼ 0.025 and P ¼ 0.024, respectively), as did the source of stem cells, patients receiving umbilical cord blood transplants showing significantly lower levels of both IFN-g T-cell subsets than those receiving BM or peripheral stem cell transplants (P ¼ 0.025 for IFN-g CD8 þ T cells, and P ¼ 0.046 for IFN-g CD4 þ T cells). Patients receiving transplants from HLA-matched donors, undergoing nonmyeloablative conditioning or receiving MTX showed higher levels (not statistically significant) of both IFN-g T-cell subsets than patients receiving transplants from HLA-mismatched donors, who had undergone myeloablative conditioning or receiving mycophenolate mofetil (not shown).
Non-significant tendencies to display more frequently IFN-g CD8 þ and IFN-g CD4 þ T-cell responses within the protective range were observed in patients receiving transplants from CMV seropositive, related or HLAmatched donors, BM or peripheral stem cell grafts and in CMV-specific immunity in allo-SCT patients N Tormo et al patients who had undergone non-myeloablative conditioning, or were not treated with mycophenolate mofetil (Table 3) . By day þ 90, the same tendencies as for the median number of both CMV-specific IFN-g T-cell subsets (not shown) and the frequency of patients who had achieved protective IFN-g T-cell levels (Table 3) were observed. Overall, differences between paired groups were less marked in comparison with those seen at day þ 30 (not shown), yet, the effect of HLA-matching was clearly discernable. By day þ 360, only HLA-matching, among the abovementioned pre-transplant and clinical factors, had a significant impact (P ¼ 0.010 for IFN-g CD8 þ T cells) on the frequency of acquisition of protective CMV-specific T-cell responses.
The occurrence of acute GvHD grades II-IV (median 40 days after transplantation, range 6-192 days) had no significant influence either on the degree of reconstitution of CMV-specific IFN-g T-cell responses or the frequency of patients acquiring protective levels of both T-cell subsets at days þ 90 and þ 365. The effect of the use of ATG could not be evaluated at these time points because of the limited number of available samples for analysis.
The effect of CMV DNAemia on the reconstitution of CMV-specific IFN-g CD8 þ and IFN-g CD4 þ T-cell responses was investigated. As shown in Table 4 , levels of IFN-g CD8 þ and CD4 þ T cells in patients who had CMV DNAemia were not significantly different from those in patients with no documented CMV DNAemia at any time point. In fact, T-cell levels above protective thresholds were reached by a comparable number of patients at day þ 90 (Table 3 ) or þ 365 (not shown) irrespective of whether they did or did not have a preceding episode of CMV DNAemia. Neither the duration nor the peak value of CMV DNAemia was significantly correlated with IFN-g CD8 þ and CD4 þ T-cell levels at any time point (PX0.5). Nevertheless, higher net increments in the median levels of both T-cell subsets by days þ 60 and þ 90 (from baseline counts at day þ 30) were observed in patients who experienced CMV DNAemia than in patients with did not (Table 4) . 
Discussion
Previous studies performed by our group showed that CMV pp65 and IE-1-specific IFN-g CD8 þ and CD4 þ T cells have a major role in protection from CMV DNAemia and in control of CMV replication during episodes of active CMV infection. 14, 19, 20 In a pilot study, we found significantly lower IFN-g CD8 þ and CD4 þ T-cell levels at day þ 30 in patients who later developed an episode of CMV DNAemia than in patients who did not experience it, and defined threshold levels of both T-cell subsets predicting protection from CMV DNAemia with maximum specificity and positive predictive value (41.0 cell/mL for IFN-g CD8 þ T cells and 41.2 cells/mL for IFN-g CD4 þ T cells).
14 In this study, we confirmed our earlier findings in a much larger cohort and proved the reliability of these surrogate markers in identifying patients presumably protected from CMV DNAemia within the first 120 days after transplantation. Unfortunately, both IFN-g T-cell markers performed rather modestly in their ability to predict the occurrence of CMV DNAemia; in fact, CMV DNAemia was not documented in a relevant fraction of patients displaying levels of both T-cell subsets below the defined thresholds for protection, or even in patients with undetectable T-cell responses. It might be that the levels of CMV-specific T-cells conferring protection from active CMV infection vary among patients, perhaps depending on their latent CMV burden. It is also possible that enumeration of CMV-specific T cells exhibiting multifunctional rather than monofunctional properties provides a more precise estimation of the overall state of immune competence against CMV, as has been suggested in previous studies. 13, [21] [22] [23] [24] [25] In addition, T-cell responses against viral proteins other than pp65 and IE-1, or other functional anti-CMV immune responses such as those mediated by NK cells, which may critically contribute to the control of CMV infection, were not examined in this study. 26, 27 Clearly, the IFN-g CD4 þ T-cell marker performed worse than the IFN-g CD8 þ T-cell marker in predicting the risk of CMV DNAemia. In this sense, it has to be taken into consideration that our analytical method is less suited for assessing CMV-specific CD4 þ than CD8 þ T-cell responses (use of overlapping peptide libraries and pp65 and IE-1 as stimulating Ags). 6 Cutoff cell levels of CMV-specific IFN-g-producing T cells affording protection from CMV pp65-antigenemia, DNAemia or end-organ disease either coincident or remarkably close to those proposed herein have been previously reported. [11] [12] [13] 15 Notably, Ohnishi et al. 12 found that CMV antigenemia was not observed in patients who had over 1 cell/mL in the enzyme-linked immunosorbent spot assay using individual pp65 peptides as Ags. In another study, levels of IFN-g CD8 þ and CD4 þ T cells above 3 and 1 cell/mL, respectively, as enumerated by ICS using CMV VR1814-infected DCs as stimulating Ag, defined immune protection against a high risk of CMV disease. 13 Likewise, Hebart et al. 11 found that the presence of more than five pp65-peptide-specific IFN-g CD8 þ T cells/mL was associated with protection from CMV DNAemia.
In this study, early and long-term reconstitution of CMV-specific IFN-g CD8 þ and IFN-g CD4 þ T-cell responses occurred to the same extent in patients with or without previous documented CMV DNAemia. Moreover, no significant correlation was found between either the duration (and by inference, the cumulative ganciclovir dose received) or the peak level of CMV DNAemia with the degree of immune reconstitution. Our data seem to be in conflict with previously published results showing that prophylactic administration of ganciclovir blunted the reconstitution of CMV-specific T cells, 3 but are in keeping with recently published data indicating that recovery of functional CMV-specific T-cell populations occurs irrespective of documented active CMV infection. 28, 29 Nonetheless, CMV DNAemia appeared to have a booster effect on the kinetics of reconstitution of both T-cell populations.
In our cohort, recipients of grafts from CMV-seronegative, unrelated or HLA-mismatched donors showed a poorer CMV-specific IFN-g CD8 þ and CD4 þ T-cell responses at day þ 30 in comparison with that of patients receiving transplants from CMV seropositive, sibling or HLA-matched donors. In fact, the latter patients tended more frequently to display IFN-g CD8 þ or IFN-g CD4 þ T-cell numbers above the protective cutoff cell levels than the former patients throughout the study period. This may account in part for the differences in the incidence of CMV DNAemia observed between these paired groups. At later times (days þ 90 and þ 365), both the magnitude of the CMV-specific IFN-g þ T-cell responses and the frequency of patients showing protective levels of both T-cell populations tended to equate, most likely as a result of the booster effect of CMV replication on T-cell reconstitution. Yet, the effect of HLA-matching was clearly discernable at day þ 90, and even at day þ 365. Our data support previous findings suggesting that the CMV serostatus of the donor critically influences the rate and magnitude of CMV-specific T-cell reconstitution. 3, 13, 21, 22, 24, 30, 31 Our data are also in accordance with previously published results indicating that overall, T-cell reconstitution, and specifically CMV-specific T-cell recovery, are notably delayed in recipients of grafts from unrelated or HLA-mismatched donors. 21, 28, 32 In line with previous findings, 12,28 the use of ATG had a profound impact on the magnitude of recovery of CMV-specific T-cell immunity at day þ 30 (it could not be evaluated later on). Likewise, the use of mycophenolate mofetil instead of MTX in the GvHD prophylaxis regimen was associated with a poorer CMV-specific T-cell response, particularly at day þ 30. The latter findings may account for the higher incidence of CMV DNAemia observed in patients receiving ATG or mycophenolate mofetil.
We found that recipients of umbilical cord blood transplants had poorer CMV-specific T-cell reconstitution with respect to that of recipients of BM or peripheral stem cells. Contrarily, the frequency and magnitude of reconstitution of both functional T-cell subsets appeared to be comparable for recipients of BM and peripheral stem cell transplants. Conflicting data have been published on this issue. 13, 28, 31 In this study, the conditioning regimen had no significant influence on the rate and magnitude of recovery of CMVspecific IFN-g T-cell responses, though, patients who had undergone non-myeloablative conditioning had tendencies to reach more frequently protective levels of both T-cell subsets throughout the study period. A beneficial effect of non-myeloablative conditioning on the reconstitution of CMV-specific T-cell immunity in comparison with myeloablative conditioning has been reported by other groups. 21, 31 Finally, the occurrence of acute GvHD (grades II to IV) had no significant effect on the magnitude of CMV-specific T-cell reconstitution. Our data, nevertheless, should be interpreted with caution given the scarce number of patients with moderate-to-severe acute GvHD for whom immunological data were available. Nonetheless, discrepant data have been published on this subject. 13, 28, 31 which may be because of the differences in the timing of immunological monitoring after the implementation or cessation of corticosteroid therapy and the cumulative dose administered prior to sampling. In summary, we have further delineated the effects of pre-transplant and clinical factors as well as the influence of active CMV infection on the magnitude and kinetics of reconstitution of CMVspecific IFN-g CD8 þ or IFN-g CD4 þ T-cell responses within 1 year after transplantation. More importantly, the data presented herein suggest that immunological monitoring may help to stratify allo-SCT patients according to their relative risk of developing CMV DNAemia. This may allow for personalization of pre-emptive antiviral therapies, which may translate into tangible benefits for the patients.
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